Lupus Nephritis
Lupus Nephritis
复制标题
DOI：
10.1097/maj.0b013e3181907b3d
复制
发表时间：
2009-06-01
影响因子：
3.1
通讯作者：
Saxena, Ramesh
中科院分区：
文献类型：
--
作者：
Singh, Sandeep;Saxena, Ramesh
狼疮性肾炎(LN)是系统性红斑狼疮的常见表现之一。肾活检仍然是诊断LN的主要方法，通常由尿沉渣异常、蛋白尿或肌酐升高引起。国际肾脏病学会/肾脏病理学会的新分类倾向于消除世界卫生组织分类的模糊性，并导致对患者进行更好的分类。尽管联合使用细胞毒性和类固醇治疗可以改善LN的预后，但多达20%的患者进展为肾功能衰竭。此外，目前方案的毒性仍然是一个主要问题。在过去的几十年里，人们在认识LN的发病机制方面取得了巨大的进展，但在针对LN的治疗中加入了一些新的手段，给内科医生留下了一些选择。幸运的是，随着参与疾病发病机制的分子过程的展开，丁胺治疗的新靶点出现了。这些药物是否会被证明更有效、毒性更低仍是一个有争议的问题，将通过几项正在进行的试验和未来的研究来回答。
Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus. Kidney biopsy remains a mainstay of LN diagnosis, Which is usually prompted by abnormal urinary sediment, proteinuria, or elevated creatinine. New International Society of Nephrology/Renal Pathology Society classification of LN tends to remove sonic of the ambiguities of World Health Organization classification and results in better categorization of patients. Although prognosis of LN has improved with the combined use of cytotoxic and steroid therapy, up to 20% of these patients progress to renal failure. Moreover, toxicity of the current regimens remains a major concern. Last few decades have seen a tremendous progress being made ill understanding the pathogenesis of LN, but a little has been added to armamentarium against LN, leaving physicians with a few choices. Fortunately, with unfolding of molecular processes involved in disease pathogenesis, new targets for ding therapy have emerged. Whether these medications will prove to be more efficacious and less toxic remains a matter of debate and will be answered by several ongoing trials and future Studies.